The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation and behavior from their labels following an investigation, the agency stated in a Jan.

UPDATE (January 5, 2026): The future of the Food and Drug Administration (FDA) 's proposed ban on hair-straightening products containing formaldehyde is now uncertain, as the organization just missed its self-imposed deadline of December 2025 to act.

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss drugs. The U.S.

The Food and Drug Administration (FDA) updated its guidance on Tuesday to allow more wearables to fall into a general wellness category and skip the agency's expensive review process befo | FDA Commissioner Marty Makary announced changes to FDA guidance that allow more devices to fall into the unregulated wellness category,

In a pair of guidance documents released Tuesday, the regulator clarified the types of wellness features and clinical decision support tools that don’t fall under medical device oversight.

Certain people risk severe or life-threatening reactions if they consume these products, according to an official alert.

Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the reshoring of pharmaceutical manufacturing.